Incidence and Impact of Non-CMV Herpes Viral Infection in Haploidentical and Matched Sibling Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis

Single-center studies have reported increased risk of CMV infection in patients undergoing allogeneic transplant using haploidentical graft with post-transplant cyclophosphamide (HaploCy), however limited data exists regarding the impact of this transplant platform on the incidence of non-CMV herpes viruses (NCHV) infection (viremia/disease). Furthermore, it is unclear if the donor type or altered immune reconstitution resulting from the use of PTCy contributes to this infection risk. To study this, patients reported to the CIBMTR with AML/ALL/MDS transplanted between 2012 and 2017 receiving HaploCy (n  = 757), matched-sibling donors receiving PTCy (SibCy, n=403), or matched sibling with calcineurin inhibitor and methotrexate/mycophenolate mofetil (SibCNI, n=1605) with either marrow or peripheral blood grafts were examined (Table 1).

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Anurag K. Singh, Ephraim J. Fuchs, Asad Bashey, Stefan O. Ciurea, Scott R. Goldsmith, Siddhartha Ganguly, Randy Taplitz, Carolyn Mulroney, Richard T. Maziarz, Soyoung Kim, Min Chen, Roy F. Chemaly, Krishna V. Komanduri, Miguel Perales, Rizwan Romee, Marci Tags: 507 Source Type: research